TARO - Jazz Pharma files patent infringement suit against Teva Taro over generic Epidiolex

• Jazz Pharmaceuticals ( NASDAQ: JAZZ ) has filed a patent infringement lawsuit against several generic drugmakers for submitting abbreviated New Drug Applications (aNDAs) to the US FDA to market generic versions of Epidiolex (cannabidiol).
• Teva Pharmaceutical Industries ( NYSE: TEVA ) and Taro Pharmaceutical Industries ( NYSE: TARO ) are among the named defendants.
• Epidiolex was approved in 2018 for treatment of seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex.
• Jazz ( JAZZ ) claims Epidiolex has Orphan Drug Exclusivity for seizures associated with Lennox-Gastaut syndrome or Dravet syndrome in patients 2 years and older through September 28, 2025, and for the treatment of seizures associated with Lennox-Gastaut syndrome or Dravet syndrome in patients between 1 and 2 years of age and for the treatment of seizures associated with tuberous sclerosis complex through July 31, 2027.

For further details see: